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Introduction 13
A subpopulation of cancer cells often remains alive even after successful therapy has 14 eliminated most tumor cells. Those surviving cancer cells are the prime source for recurring 15 tumors and the ultimate failure of therapy. Therefore, understanding the mechanisms that 16
allow therapy-tolerant cancer "persister" cells is fundamental for developing strategies to 17 defeat drug resistance. 18
Most cancers tend to be heterogenous and genetically plastic, as they frequently express has the potential to access all the cellular mechanisms encoded in the genome and drug 22 treatment will select for those cells that happen to have adopted an escape mechanism. 23
Well-known examples of drug resistance strategies to traditional chemotherapies include 24 upregulating efflux pumps or drug metabolizing enzymes. Recently, more specific 25 mechanisms for surviving newer, more selective therapies have been observed. These 26 include mutations in drug targets that prevent drug binding (Janne, 2008; Pao et al., 2005) 27 but perhaps more commonly the adoption of alternative, or "by-pass" mechanisms. For response to anti-RTK therapy, persisting cancer cells have switched to a GPX4-dependent 30 state and survive until anti-RTK therapy has ended. As therapeutics become more selective 31
and "personalized" to target specific vulnerabilities in a tumor, such more specific resistance 32 mechanisms can be expected. 33
Currently, anti-mitotic drugs represent a major class of cancer medicines. This class 34
includes microtubule-stabilizing drugs, such as paclitaxel and docetaxel, and destabilizing 35 agents, such as vinorelbine and vinblastine (Steinmetz and Prota, 2018). More recently 36
agents that target the kinases that regulate mitotic spindle formation and timing, such as 37
Aurora and Polo-like kinases, have entered clinical trials (Otto and Sicinski, 2017; Steinmetz 38 and Prota, 2018). 39
In the course of studying hypersensitivity to inhibitors of Aurora kinase A (Tagal et al., 2017), 40
we reported an unusual dose response relationship to Aurora kinase inhibitors. In some non-41 small cell lung cancer (NSCLC) lines, more cells survived the inhibitor treatment at high than 42
at lower drug concentrations. Survival of a small remnant population after treatment with 1 anti-mitotic drugs is a common observation. A prominent current explanation for this cell 2 population is called "mitotic slippage" (Sinha et al., 2019) . This concept assumes that some 3 cells manage to struggle through mitosis without triggering an apoptotic response and 4 subsequently either leave the proliferative cell cycle or continue to "slip" through it. 5
However, alternative cell cycles are normally used for the production of particular cell types 6 and tissues such as megakaryocytes, placental trophoblasts or hepatocytes in mammals 7
(Edgar et al., 2014; Gupta, 2000; MacAuley et al., 1998; Ravid et al., 2002) . This class of 8 alternative cell cycles, which do not require a mitotic machinery, could provide a survival 9 mechanism by avoiding the catastrophic consequences of anti-mitotic perturbagens. We 10
show in the work presented below that many NSCLC cell lines grow by adopting an 11 endocycle when Aurora kinases are inhibited. However, unlike normal cells for which 12 endocycles are part of terminal differentiation, a subset of endocycling NSCLC cells can re-13 enter the proliferative cell cycle after Aurora kinase inhibitors are withdrawn. 14
Results 15
Aurora kinase A is an important regulator of mitosis and functions in the assembly of the cancer drug candidates (Otto and Sicinski, 2017) . In a previous study, we investigated these 19 inhibitors and observed an unusual drug response relationship with an Aurora kinase A 20 inhibitor, MLN8237/Alisertib (MLN8237 henceforth) (Tagal et al., 2017) . In contrast to the 21 standard sigmoidal or monophasic dose-response phenotypes ( Figure 1A , C), a subgroup of 22 cell lines treated with MLN8237 exhibited a multiphasic "camelback" drug-response pattern 23
( Figure 1E ). VX-689, another Aurora kinase A inhibitor, also caused a similar response 24 pattern in the same panel of non-small cell lung cancer (NSCLC) lines ( Figure 1B , D, F).
25
This unexpected drug response pattern of increased cell survival at higher drug 26 concentrations suggested that secondary targets of these inhibitors might control a 27 mechanism leading to drug resistance. This would be of concern, since peak plasma 28
concentrations of MLN8237 in humans reach 3 µM, well above the concentration at which it 29 selectively inhibits its primary target (Cervantes et al., 2012). Thus, it was of interest to 30
identify the secondary targets of Aurora A inhibitors and the respective drug resistance 31 mechanism. 32 NSCLC line NCI-H1693 was selected as representative of cell lines capable of this unusual 33
dose-response because it had the most dramatic phenotype with 35% of the cells growing at 34 87% of the rate of an untreated population in the presence of higher, potentially non-35
selective concentrations of MLN8237 (Figure 2A ). NCI-H1693 cells had a first phase EC50 36 of 23 nM for MLN8237 and 64 nM for VX-689 (Figure 2A , C). The EC50s of MLN8237 and 37 VX-689 for the second, "restorative" phase in which the viability increased, was 180 nM and 38 26 µM, respectively. At the highest and clinically irrelevant concentrations (Phase 3), 39
MLN8237 gains a "general toxin" characteristic, which was not investigated in this study. In 40 parallel, we measured Caspase 3/7 activity to determine if apoptotic cell death occurred in 41 the presence of MLN8237 and VX-689 at any of concentrations measured. Apoptosis was 42
first significantly detected at 16 nM for MLN8237 and 47 nM for VX-689. However, caspase 43 activation was not detected during the second phase of the response to each drug ( Figure  44 2B, D). In an orthogonal assay for cell growth, NCI-H1693 cells were stained with crystal 1 violet after seven days treatment with either MLN8237 or VX-689 and cell densities were 2 compared with the density of cells stained on day 0. We found that growth of NCI-H1693 3 cells was inhibited at Aurora A-selective concentrations and was restored at 410 nM and 4
33.3 µM of MLN8237 and VX-689, respectively ( Figure 2E , G). Thus, the second phase of 5 response to these two inhibitors not only helped NCI-H1693 cells survive, but also restored 6 their growth. B and C are two orthologues of Aurora A in humans and their high degree of homology is a 10 well-known challenge for creating inhibitors specific to Aurora kinase A. Therefore, Aurora B 11
and Aurora C were obvious candidates for the proteins responsible for reversing cytotoxic 12 effects at higher concentrations of Aurora A inhibitors. Aurora kinases auto-phosphorylate 13 when bound to their activators and their phosphorylation levels directly indicate their 14 activation status in cells. In addition, Histone H3 is a well-characterized substrate of Aurora 15
kinases B and C, and its phosphorylation at Serine 10 is established to be a direct marker of 16
Aurora B, C and Histone H3, was not detected; but Aurora A was phosphorylated ( Figure 3A, B ).
36
This indicated that at those concentrations, NCI-H1693 cells were arrested in mitosis at a 37 point after activation of Aurora A. However, starting at 1.23 µM for AZD1152 or 140 nM for 38 GSK1070916, phosphorylation of Aurora A was not detected, indicating that both drugs also 39
inhibit Aurora A at higher concentrations. 40
The dose-response pattern of viability of NCI-H1693 cells to AZD1152 and GSK1070916 41 resembled the multiphasic "camelback" response of those cells to Aurora A selective 42
inhibitors MLN8237 and VX-689 ( Figure 3C -F). AZD1152 and GSK1070916 each caused 43 significant reduction in viability of NCI-H1693 cells at concentrations selective for Aurora B 44 and C. However, growth was restored when NCI-H1693 cells were treated with 1 concentrations above 1.23 µM and 140 nM of AZD1152 and GSK1070916, respectively 2 ( Figure 3G -H), where they began to antagonize Aurora A as a secondary target. These data 3
suggested that inhibiting Aurora A or Aurora B and C activities alone caused significant 4 mitotic catastrophe leading to cytotoxicity; but inhibition of all three Aurora kinases together 5 did not ( Figures 3I, J) . 6
To ensure that Aurora kinases A, B and C, but not a previously unrecognized fourth target, 7
are solely responsible of restoring viability induced with individual treatments of each of 8 these four inhibitors, we treated NCI-H1693 cells with these four inhibitors as doublet 9
combinations at concentrations where they are selective for their primary targets ( Figure 4A , 10 B). Combination therapy of Aurora A and Aurora B, C inhibitors did not cause additive or 11 synergistic cytotoxicity; but instead allowed cell survival and growth ( Figure 4C , E). We 12 measured the activities of Caspase 3/7 ( Figure 4D , F) and crystal violet staining ( Figure 4G , 13 I) to assess apoptosis and cell growth. Inhibiting the Aurora kinases together allowed NCI-14
H1693 cells to survive and grow whereas inhibiting Aurora A or B selectively was inhibitory. 15
Consequently, selective concentrations of Aurora B, C inhibitors could convert the 16 multiphasic "camelback" dose response pattern of Aurora A inhibitors into monophasic 17
"resistant" dose response pattern when combined together in NCI-H1693 cells ( Figure 4H Based on these observations, we hypothesized that pan-Aurora kinase inhibitors would be 20
non-or minimally effective on NCI-H1693 cells when compared with the first response 21
phases of MLN8237, VX-689, AZD1152 and GSK1070916. We performed biochemical 22 assays identical to the ones performed with the four Aurora A or B and C selective inhibitors. 23
We observed that pan-Aurora inhibitors, VX-680/Tozasertib (VX-680 henceforth) and PHA-24
739358/Danusertib (PHA-739358 henceforth) have a resistance response pattern 25
resembling the second phase of multiphasic response of the first four selective inhibitors 26
( Figure S1A -H). 27
To determine how frequently NSCLC cell lines survived simultaneous inhibition of all Aurora 28 kinases, we measured the dose-responses to MLN8237 in a panel of 77 NSCLC and 4 29
immortalized human bronchial epithelial cell (HBEC) lines. More than fifty percent of these 30
cell lines had a multiphasic camel-back drug response pattern with more cancer persister 31 cells at the pan-Aurora kinase inhibitory phase in comparison to the responses at lower 32
Aurora A-selective doses ( Figure 5A ). In addition, the rest of tested NSCLC lines were either 33
uniformly sensitive or uniformly resistant to the effective doses of MLN8237 with a sigmoidal 34 or monophasic response, respectively ( Figure 5A ). An identical screen with VX-689 35
produced results similar to those obtained with the screen of MLN8237 ( Figure 5B ). In these 36 studies, Erlotinib, an EGFR-targeted therapy agent and FDA-approved drug for NSCLCs, 37
was used as control in parallel to MLN8237 and VX-689, on the same day at identical 38 conditions and no multiphasic "camelback" response pattern was observed ( Figure 5C ). 39
Overall, our data indicated that the multiphasic response pattern against Aurora A inhibitors 40
is common for NSCLC cell lines and more "persister" cells were generated when all Aurora 41 kinases were inhibited in comparison to selective Aurora A inhibition.
42
To determine what type of growth cells adopt after the loss of Aurora kinase signaling, we 43 examined cellular morphology and DNA content after inhibiting Aurora kinases individually or 44 in combination. After the inhibition of Aurora kinases with the non-selective high 1 concentration of MLN8237, we observed that NCI-H1693 cells grow substantially in size 2 instead of numbers and therefore, cellular ATP levels increase similar to untreated 3 proliferating cells ( Figure 6A -B). The average area of cells treated with pan-Aurora kinase 4
inhibitor for four days increased and cells had much more nuclear DNA in comparison to the 5 untreated ones ( Figure 6C ). Cell numbers were not increasing ( Figure 6D ) in the treated 6
samples, but were balanced by increasing the cellular size. Therefore, total ATP levels 7 present in the treated wells remained similar to the wells with untreated cells. DNA 8
replication also continued ( Figure 6D ). Increasing DNA content and cell size are 9
characteristics of an endocycle (Lee et al., 2009 ). Overall, our findings suggest that after 10
inhibiting Aurora kinase signaling, cells omit all or most of mitosis, and continue with intact 11
Gap (G) and Synthesis (S) phases of cell cycle (Figures 6E) . 12
If an endocycle variant takes place and mitosis is avoided when Aurora kinase signaling is 13
turned off, we hypothesized that mitotic machinery including spindle-related components and 14
regulators should partially or completely be dispensable. Thus, cells would be non-15
responsive to anti-mitotic agents under these conditions instead of causing additive or 16
synergistic effects whereas perturbing interphase cellular machineries should remain 17 cytotoxic ( Figure 7A ). Thus, we tested NCI-H1693 cells with 17 anti-cancer or cytotoxic 18 agents including 9 for interphase (Gemcitabine, Carboplatin, Cisplatin, Etoposide, 19
Topotecan, Doxorubucin, Pemetrexed, Methotrexate, 5-Fluorouracil, Aphidicollin and 20
Bafilomycin A) and 8 for mitosis (Paclitaxel, Docetaxel, Vinorelbine, Vinblastine, PLK1 21
inhibitor BI-6727 (Volasertib), CENPE inhibitor GSK923295, EG5 inhibitors Ispinesib and 22
VS-83). For the cell viability assessments, the EC100 of each agent was used 23
( Supplementary Table 1 ). Aurora kinase inhibition prevented toxicity from all anti-mitotic 24
drugs whereas cells were sensitive to interphase perturbagens regardless of the presence of 25
Aurora inhibitors ( Figure 7B ). In addition to individual treatments with these anti-cancer 26 agents, we also added a cocktail of the eight anti-mitotic agents to our survey and observed 27 that cancer persister cells generated by pan-Aurora kinase inhibition were able to avoid 28 death even in that extreme condition ( Figure 7B ). In parallel to the cell viability assays, we 29 stained NCI-H1693 cells with crystal violet to check the status of cell growth on day 7 in 30
comparison to the cell density on Day 0. Our results confirmed that NCI-H1693 cells 31
survived and continued to grow in the presence of all anti-mitotics and their cocktail, but not 32 the anti-interphase perturbagens ( Figure 7C ). Lastly, we quantified the extent of tolerance of 33 these anti-mitotic persister cells to individual anti-mitotic agents by performing cell viability 34 assays with serial concentrations of eight anti-mitotic drugs in the presence and absence of 35
pan-Aurora kinase inhibitors. We observed at least 4 logarithmic (log) magnitude of drug 36 resistance to Paclitaxel, 5 logs to Docetaxel ( Figure 7D ), and at least 2 logs of significant 37 resistance to others ( Figure S2A-F) . 38
Finally, we investigated whether the NCI-H1693 cells that had switched to endocycle could 39
reenter the proliferative cell cycle. Four days after inhibiting Aurora kinase signaling with 40 combinations of Aurora A inhibitor, MLN8237 and Aurora B, C inhibitors AZD1152 or 41 GSK1070916 at concentrations selective for their primary targets, the media with the 42
combination treatments was washed out and NCI-H1693 cells were allowed to grow in the 43 absence of any drug treatments for 14 days. NCI-H1693 cells recovered from the 44 combination treatment and were able to form colonies, indicating the ability of cells to 45 reenter the mitotic cell cycle ( Figure 7E ). In comparison, NCI-H1693 cells treated with 1
Paclitaxel had significantly fewer colonies. These observations indicate that loss of Aurora 2 kinase signaling initiates an endocycle, which maintains cell growth in size instead of 3 numbers. These cells can re-enter a proliferative cell cycle when Aurora kinase signaling is 4 restored ( Figure 7F ). 5
Discussion 6
Our results indicate that Aurora kinases function together to keep the cell in a proliferative 7 cell cycle. In many cell types, only Aurora A and B kinases are expressed and the extent to 8
which Aurora C plays a role in this activity is not determined by our work. In a majority of 9
NSCLC cell lines, chemical inhibition of all family members of Aurora kinases allows the 10 cells to adopt an alternative cell cycle where cells continue to replicate DNA and grow in 11 size, but do not divide. In this state, cells are resistant to all anti-mitotic drugs tested 12
because the mitotic machinery is no longer engaged. Our findings together suggest that 13
Aurora were used for immunofluorescence assays. 19
Microplate drug sensitivity assays 20
NCI-H1693 cells (3,000 per well) were seeded in 96-well plates and incubated at 37 °C for 21 24 h. Treatment with vehicle (DMSO) or serial dilutions of the indicated compounds in 9 22
concentrations from 1 to 33,300 nM were performed in triplicate (final DMSO 23
concentration=0.34% in all wells). After 96 h, media were removed and cell viability was 24 measured with a CellTiter-Glo assay (Promega, G7573). 25
A dose-response study of a panel of NSCLC and HBEC cell lines with MLN8237 (Alisertib), 26
VX-689 and Erlotinib was performed in 384-well plate format. Cells were dispensed at a 27 density of 1,000-1,500 cells per well with an automated liquid dispenser (BioTek MicroFlo; 28
Thermo-Fisher, Inc.). Each concentration was screened in triplicate. Cells were incubated for 29 24 h at 37 °C in the presence of 5% CO2.with an automated liquid dispenser (BioTek 30
MicroFlo; Thermo-Fisher, Inc.) Drugs/chemicals were dosed in DMSO at 12 concentrations 31 ranging from 50 pM to 50 μM (half-log dilutions) in triplicate, using an Echo 555 acoustical 32 transfer instrument. After incubating the cells at 37 °C for 96 h, cell viability was measured 33
with a CellTiter-Glo assay. The comparative tests of three agents were performed on the 34 same days, in identical conditions. Dose responses of each cell line to each agent were 35 assessed at the indicated concentrations individually. Concentrations that caused increase 36 in the measured viability after the initial cytotoxic effect of respective agent were colored in 37 red. 38
Microplate apoptosis assay 39
Treatments of the indicated compounds were performed in the same manner with the 40 microplate drug sensitivity assays in 96-well plate format. 48 hours after treatments, culture 41 media were removed by centrifuging the assay plates upside down in liquid-collecting 42 containers at 30g for 1 min. Caspase 3 and/or 7 activity was assessed with Caspase-Glo 3/7 43 assay purchased from Promega (G8090). 44
Crystal violet staining assay 45
NCI-H1693 cells (1 × 10 5 per well) were seeded in 6-well plates and incubated at 37 °C for 1 24 h. Treatment with vehicle (DMSO) or serial dilutions of the indicated compounds in 10 2 indicated concentrations were performed (final DMSO concentration=0.34% in all wells). 3
After seven days, media were removed and cell growth was assessed with a crystal violet 4 staining assay solution (6% glutaraldehyde, 0.5% crystal violet (w/v) in water). 5
Western blotting 6
In all, 2 × 10 5 cells were treated with the indicated compounds at indicated concentrations in 7 six-well format. Forty-eight hours after treatments, the culture medium was aspirated and 8 cells were washed with PBS. Cells were lysed in RIPA lysis buffer (50 mM Tris buffer pH 8, 9
150 mM NaCl, 1% NP-40, 0.5% sodium, 0.1% SDS, 0.5% Sodium deoxycholate) 10
supplemented with protease and phosphatase inhibitors. The protein concentrations of cell 11 lysates were measured with the Protein DC assay (Bio-Rad, 500-0111). Phosphorylation of 12 histone H3 and Aurora kinases A, B, C, and β-Actin expression as internal control were 13 monitored by immunoblotting with monoclonal antibodies. 14
Light microscope and immunofluorescence assay 15
Cells in transparent bottom plates were fixed with 4% formaldehyde in PBS for 15 min at 16 room temperature. After washing with PBS, cells were permeabilized with 0.25% Triton-X in 17
PBS for 15 min at room temperature. After washing with PBS, cells were incubated with 10% 18
Bovine Serum Albumin (BSA) blocking solution for 1 h. Next, cells were immunostained with 19
Texas Red™-X Phalloidin and/or Hoechst 33342 reagent for 1 h. Microscopic observations 20
were performed on an EVOS FL Cell Imaging System. Mean nuclear area of cells after the 21 treatments with the indicated compounds were calculated with the ImageJ software and 22
graphed. 23
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